EMA grants orphan drug status to remestemcel-L (ProchymalT) for acute graft versus host disease
Source: BioSpace
Area: News
The European Medicines Agency (EMA) has granted orphan drug designation to remestemcel-L (ProchymalT) for acute graft versus host disease (GvHD).
Prochymal is an intravenous formulation of adult human mesenchymal stem cells that is currently approved in Canada and New Zealand for the management of acute GvHD in children and is available for adults and children in eight countries including the United States, under an Expanded Access Program.
Source: NeLM - News - Category: Drugs & Pharmacology Source Type: news
More News: Children | Drugs & Pharmacology | European Medicines Agency (EMA) | Grants | Stem Cell Therapy | Stem Cells